Due to the discovery of all of these increased risks, experts are now predicting that patients who received the drug eluding stents will be required to take the expensive blood-thinning drug Plavix for life.
In a few short years, these new stents have become one of the best selling devices in medical history. In 2005, about 1.5 million patients were implanted with drug-eluting stents in the US alone, with the market dominated by the Taxus stent from Boston Scientific, and the Cypher from Cordis, a Johnson & Johnson company. Cypher received FDA approval in 2003, and Taxus was approved a year later.
A market analysis in the January/February 2006, issue of Medical Device Link, reported that the worldwide market for drug-eluting coronary stents reached an estimated $4.2 billion in 2004 and is expected to nearly double by 2010.
The Taxus is by far the company's biggest moneymaker.
Of Johnson & Johnson's seven device units, Cordis is by far the most profit enhancing. In 2005, its sales grew 24% to $4 billion.
Critics have long criticized the outrageous price because according to Dr Mitchell Krucoff, of Duke Clinical Research Institute, Durham, NC, in Heartwire on February 7, 2006, "In the case of first-generation DES, these are essentially bare-metal stents that have been spray-painted with plastic." The August 6, 2004 Boston Globe describes these medical devices as:
"Stents are wire mesh devices placed in arteries, which are blocked by fatty deposits. Doctors thread a tiny balloon into the artery and inflate it to clear the blockage. Then, a stent is inserted into the artery, and a second balloon expands the stent to keep the newly cleared blood vessel wide open.
"The newest stents are coated with drugs to prevent tissue buildup within the arteries, which can create fresh blockages after the stent is in place."
However, the drug-eluding stent hay-day looks like it may be short lived. The results of studies revealed over the past several months set off alarm bells among heart specialists leading many to say they will return to the use of bare-metal stents.
The studies including the BASKET-LATE study, presented at the March 2006 American College of Cardiology Scientific Sessions in Atlanta, and most recently, the Camenzind meta-analysis presented at the September 2006 European Society of Cardiology Annual Meeting/World Congress of Cardiology Meeting in Barcelona, Spain.
The researchers found that drug-coated stents raise the risk of fatal blood clots and said the danger is greatest for patients with J&J's Cypher, who face a 38% higher risk of adverse events.
For people who develop a clot, experts say, it can be a matter of life and death because a clot inside the stent can stop the blood flow to the heart itself.